A high-risk 70-gene signature is not associated with the detection of tumor cell dissemination to the bone marrow
PURPOSE: The 70-gene signature (70-GS) is a prognostic tool, grouping patients in risk groups to assess their need for adjuvant chemotherapy. Tumor cell dissemination to the bone marrow is a marker of minimal residual disease and associated with impaired survival. In this study, we aimed to evaluate...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
27 January 2018
|
| In: |
Breast cancer research and treatment
Year: 2018, Volume: 169, Issue: 2, Pages: 305-309 |
| ISSN: | 1573-7217 |
| DOI: | 10.1007/s10549-018-4679-0 |
| Online Access: | Verlag, Volltext: http://dx.doi.org/10.1007/s10549-018-4679-0
|
| Author Notes: | Vincent P. Walter, Florin-Andrei Taran, Markus Wallwiener, Christina Walter, Eva-Maria Grischke, Diethelm Wallwiener, Sara Y. Brucker, Andreas D. Hartkopf |
| Summary: | PURPOSE: The 70-gene signature (70-GS) is a prognostic tool, grouping patients in risk groups to assess their need for adjuvant chemotherapy. Tumor cell dissemination to the bone marrow is a marker of minimal residual disease and associated with impaired survival. In this study, we aimed to evaluate whether 70-GS is associated with the presence of disseminated tumor cells (DTCs) in the bone marrow of patients with early breast cancer. - METHODS: In patients with hormone receptor-positive HER2-negative early breast cancer, the 70-GS was obtained and the presence of DTCs was immunohistochemically evaluated using cytokeratin staining with the A45-B/B3 antibody. - RESULTS: 149 patients were included into the analysis. 40 (27%) had a high-risk 70-GS and 35 (23%) had detectable DTCs in their bone marrow. 9 (22%) of the 40 patients with high-risk 70-GS and 26 (24%) of the 109 patients with a low-risk 70-GS were positive for DTCs (p = 0.863). - CONCLUSIONS: As both 70-GS and DTC detection are known prognostic factors but do not seem to correlate, a follow-up on a larger cohort is warranted to evaluate if a combination of the two is able to better stratify the relapse risk in early breast cancer patients. |
|---|---|
| Item Description: | Gesehen am 29.04.2019 |
| Physical Description: | Online Resource |
| ISSN: | 1573-7217 |
| DOI: | 10.1007/s10549-018-4679-0 |